Compare Abbott Laboratories (ABT) vs General Dynamics Corporation (GD) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abbott Laboratories vs General Dynamics Corporation — how do they compare? Abbott Laboratories trades at $95.2 (market cap $166.94B), while General Dynamics Corporation trades at $372.2 (market cap $101.31B). The key difference: Abbott Laboratories is the larger of the two by market cap, and Abbott Laboratories pays the higher dividend (2.63%). Which is the better fit depends on your goals.
| ABT | GD | |
|---|---|---|
Market Cap | $166.94B | $101.31B |
Sector | Health | Industrials |
52-Week High | $136.62 | $376.88 |
52-Week Low | $82.57 | $296.65 |
Enterprise Value | $193.69B | $107.49B |
Dividend Yield | 2.63% | 1.7% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $95.63, up 0.25% on the day, with a bullish technical signal from moving averages and strong analyst support. The stock shows solid fundamentals with a P/E of 26.79 and net income margin of 13.91%, though recent earnings have been mixed. Recent news highlights regulatory approvals for new medical devices, supporting growth prospects.
The outlook remains positive with a consensus price target of $122.55, implying significant upside. Key risks include competitive pressures and macroeconomic headwinds, but strong institutional backing and consistent dividend payments provide stability for long-term investors.
General Dynamics (GD) trades at $374.64, up 0.29% on the day, near its 52-week high. The stock shows a bullish technical trend with strong moving average signals, while fundamentals are solid with revenue growth to $52.55 billion in 2025 and net income of $4.21 billion. Recent earnings beats and a massive $130.8 billion backlog support positive momentum, with analyst consensus leaning bullish.
Outlook remains favorable given defense budget tailwinds and execution strength, but valuation multiples like P/E of 23.72 suggest limited upside from current levels. Risks include contract execution delays and macroeconomic pressures. The stock offers steady growth and income via dividends, but investors should weigh rich valuations against growth prospects.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abbott Laboratories
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →About General Dynamics Corporation
General Dynamics is a defense contractor and business jet manufacturer. The firm's segments include aerospace, combat systems, marine, and technologies. The company's aerospace segment creates Gulfstream business jets. Combat system produces land-based combat vehicles, such as the M1 Abrams tank. The marine subsegment creates nuclear-powered submarines, among other things. The technologies segment contains two main units, an IT business that primarily serves the government market and a mission systems business that focuses on products that provide command, control, computers, intelligence, surveillance, and reconnaissance capabilities to the military.
Read more on GD →
